TRDA
NASDAQEntrada Therapeutics Inc.
Website
News25/Ratings9
News · 26 weeks35-75%
2025-10-262026-04-19
Mix1790d
- Insider8(47%)
- Analyst3(18%)
- Other3(18%)
- SEC Filings3(18%)
Latest news
25 items- INSIDERSEC Form 4 filed by Wentworth Kory James4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Entrada TherapeuticsCantor Fitzgerald initiated coverage of Entrada Therapeutics with a rating of Overweight
- INSIDERSEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERChief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERCEO Doshi Dipal was granted 139,400 shares and covered exercise/tax liability with 29,050 shares, increasing direct ownership by 27% to 526,014 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERChief Financial Officer Wentworth Kory James was granted 44,600 shares and covered exercise/tax liability with 8,651 shares, increasing direct ownership by 33% to 145,975 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERPresident & COO Dowden Nathan J was granted 55,800 shares and covered exercise/tax liability with 21,261 shares, increasing direct ownership by 19% to 213,598 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERPresident, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 11,475 shares and was granted 55,800 shares, increasing direct ownership by 22% to 242,224 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- PREntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units ("RSUs") to two newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of March 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest qua
- SECSEC Form S-8 filed by Entrada Therapeutics Inc.S-8 - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECSEC Form 10-K filed by Entrada Therapeutics Inc.10-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECEntrada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- PRIndependent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients who completed dosing in Cohort 1 of the double-blinded, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiation of Cohort 2 at 12 mg/kg, a dose escalation from 6 mg/kg in Cohort 1. ELEVATE-44-201 is
- ANALYSTGuggenheim initiated coverage on Entrada Therapeutics with a new price targetGuggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00
- PREntrada Therapeutics to Present at Upcoming Investor ConferencesBOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the
- ANALYSTOppenheimer initiated coverage on Entrada Therapeutics with a new price targetOppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $21.00
- SECEntrada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- PREntrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 – -- Cash runway into Q3 2027 – -- Entrada to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) -- BOSTON, Jan. 08, 2026
- PREntrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage int
- PREntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units ("RSUs") and options to purchase 38,850 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of December 1, 2025. The options have an exercise price of $9.91 per share, which is equal to the closing price of the Company's common stock on December 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employee
- SECSEC Form EFFECT filed by Entrada Therapeutics Inc.EFFECT - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECSEC Form SCHEDULE 13G filed by Entrada Therapeutics Inc.SCHEDULE 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
- INSIDERChief Financial Officer Wentworth Kory James sold $88,932 worth of shares (8,910 units at $9.98), decreasing direct ownership by 7% to 110,026 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)